Jan Gunnar Hatlebakk
Overview
Explore the profile of Jan Gunnar Hatlebakk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
951
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El-Salhy M, Johansson M, Klevstul M, Hatlebakk J
BMC Gastroenterol
. 2025 Mar;
25(1):143.
PMID: 40050743
Background: The present study is an online survey to determine the quality of life and functional impairment caused by irritable bowel syndrome (IBS) and the healthcare experiences of IBS patients...
2.
Berentsen B, Thuen C, Hillestad E, Steinsvik E, Hausken T, Hatlebakk J
JMIR Hum Factors
. 2025 Feb;
12:e43618.
PMID: 39899743
Background: Irritable bowel syndrome (IBS) has a high worldwide prevalence and there are few effective treatment options. Patient education can influence patient behavior that subsequently may lead to changes in...
3.
El-Salhy M, Gilja O, Hatlebakk J
Microbes Infect
. 2024 Jun;
26(8):105372.
PMID: 38843950
The long-term effects of the transplant dose, its administration route and repeated faecal microbiota transplantation (FMT) on the outcomes of FMT for patients with irritable bowel syndrome (IBS) are unknown....
4.
Christensen C, Knudsen A, Arnesen E, Hatlebakk J, Sletten I, Fadnes L
Adv Nutr
. 2024 Apr;
15(5):100219.
PMID: 38599319
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), contributes to substantial morbidity. Understanding the intricate interplay between dietary factors and the incidence and progression of IBD...
5.
El-Salhy M, Hatlebakk J
Dig Dis Sci
. 2024 Mar;
69(4):1336-1344.
PMID: 38446309
Background: Previous studies showed that patients with Severe IBS respond better to fecal microbiota transplantation (FMT) than do those with Moderate IBS. Aims: The present study aimed to determine the...
6.
El-Salhy M, Gilja O, Hatlebakk J
Scand J Gastroenterol
. 2023 Dec;
59(4):391-400.
PMID: 38084725
Background: Faecal microbiota transplantation (FMT) performed with a proper protocol is a safe treatment for IBS that has high efficacy and durable effects. Females have been reported to respond better...
7.
El-Salhy M, Gilja O, Hatlebakk J
Aliment Pharmacol Ther
. 2023 Oct;
58(10):1115-1116.
PMID: 37885166
No abstract available.
8.
El-Salhy M, Gilja O, Hatlebakk J
Neurogastroenterol Motil
. 2023 Jul;
36(1):e14641.
PMID: 37427566
Background: A previous study that introduced a Fecal microbiota transplantation (FMT) protocol with a high efficacy applied a combination of favorable factors. Aims: The present study aimed to evaluate some...
9.
Pham K, Lauritzen S, Tjora E, Gilja O, Hatlebakk J, Assmus J, et al.
Scand J Surg
. 2022 Dec;
112(1):3-10.
PMID: 36484306
Background And Aims: Per oral endoscopic myotomy (POEM) has become an established treatment for achalasia, but no Scandinavian studies with long-term follow-up exist. This study from a tertiary referral center...
10.
Mazzawi T, Hausken T, Refsnes P, Hatlebakk J, Lied G
Microorganisms
. 2022 Sep;
10(9).
PMID: 36144420
Fecal microbiota transplantation (FMT) from healthy donors has been shown to improve the symptoms of irritable bowel syndrome (IBS) and changes the profile of the gut microbiota for the recipients....